Juno Therapeutics, Kite Pharma, & Petrobras Among the Morning’s Trending Stocks

Page 2 of 2

ADTRAN Reports Earnings

ADTRAN, Inc. (NASDAQ:ADTN) earned $0.25 per share on revenue of $162.7 million for the second quarter, beating the consensus estimates by $0.05 per share and $0.27 million, respectively. Earnings and sales beat estimates in part due to strong demand in the United States, particularly for the company’s FTTP and 100 megabit products. ADTRAN’s services businesses also continued their robust growth, with a revenue increase of 51% year-over-year. 11 top funds that we track owned shares of ADTRAN, Inc. (NASDAQ:ADTN) as of the most recent 13F reporting period.

Petrobras Starts Production in Field

Traders are watching Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR) shares today after the company disclosed that it has begun production at its Cidade de Saquarema unit. The production well is expected to yield a stabilized rate of as much as 30,000 BOE per day in the near future. The cash flow generated from the well will help Petrobras reduce its substantial debt burden. Traders are also watching Petrobras today due to today’s upcoming EIA report. If the EIA inventory numbers contradict yesterday’s API numbers, Petrobras could rally. 23 funds in our database had a bullish position in Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR) at the end of March, down by one quarter-over-quarter.

Follow Petroleo Brasileiro Sa Petrobras (NYSE:PBR)

AngioDynamics Beats Estimates

AngioDynamics, Inc. (NASDAQ:ANGO) beat the consensus estimates with its fourth quarter of fiscal year 2016 results, earning $0.19 per share on revenue of $93.37 million. Analysts were expecting $0.03 and $4.96 million less, respectively. For the full fiscal year 2016, AngioDynamics earned adjusted EPS of $0.58 on revenue of $353.7 million. The company expects mild growth in fiscal year 2017, predicting EPS of $0.62-to-$0.65 and sales of $355 million-to-$360 million for the fiscal year. 14 funds in our system were long AngioDynamics, Inc. (NASDAQ:ANGO) at the end of March, shares of which are up by 3.50% in pre-market trading.

Follow Angiodynamics Inc (NASDAQ:ANGO)

Disclosure: None



Page 2 of 2